residues. This included residues 190 -213 that are predicted to be intrinsically disordered; the and contained three copies each of GP1 (residues 33 -278), GP2 (residues 502 -599), heavy and Crystal structure of the 13F6-1-2 Fab fragment bound to its EBOV GP mucin-like domain (GP using the 2QHR accession number.
[18] Unlike other epitopes used in our previous and current 1 2 6 study, this structure was based on the 1976 Eckron strain. However, the alignment of the 11- chains of 13F6-1-2 antibody. (see Fig 3A) WHAT IF web server (https://swift.cmbi.umcn.nl)
was then used to add the missing atoms to the complex structure. peptide is in gray tube representation, and the heavy and the light chains of 13F6-1-2 are black. All three EBOV -antibody complexes were subjected to atomistic MD simulations using the simulations were 100 ns, and the GP -Ab100 and Ab114 production simulations were run for a simulation snapshots were saved every 1 ns resulting in 50 snapshots for each of the GP -Ab100
and GP -Ab114 systems, and 100 snapshots for the peptide -13F6-1-2 complex. Snapshots of all three complexes were analyzed using FoldX software. [21, 22] As with our 1 5 0 previous study, we initially minimize each snapshot six times in succession using the RepairPDB
command to obtain convergence of the potential energy. BuildModel command was then used to site. Finally, the binding stability of the protein complex due to each mutation was estimated the FoldX results across all individual snapshot estimates. Results and discussion
We have expanded the watch list generated by us in a previous study by including antibody 1 6 7 escape mutations against three additional antibodies interacting with EBOV GP. These watch list The EBOV GP is a class I fusion protein consisting of disulfide-linked subunits, GP1 and GP2, GP trimer (see Fig 1A) . This interaction is similar to that of KZ52, the prototypic neutralizing antibody used in our previous study. However, Ab100 contacts GP1 and GP2 of a monomer and KZ52 which interacts with GP2 of a single monomer. The epitope for Ab114 spans both the 1 7 7 glycan cap and the inner chalice of GP, (see Fig 2A) where it remains bound after proteolytic 1-2 is a monoclonal antibody that binds to an 11-residue peptide located in the heavily Table 1 and shows that they are concentrated at just six residues in KZ52 and at five residues in mutations lie at the interface as one might intuitively expect from the structure, however, most 1 9 2 mutations at the interface are not predicted to disrupt antibody binding. antibody is shown in the legend. 1-2) at a predicted amino acid sites on EBOV GP. If any of the mutations in Table 1 were to appear in a real population, it would indicate a possible mutation is present in all sequenced isolates from that outbreak. by including three more antibody complexes: EBOV GP -Ab100, GP -Ab114 and GP Mucin- (https://www.nih.gov/news-events/news-releases/nih-begins-testing-ebola-treatment-early-stage-2 5 5 trial) We hope our watch list will serve as a useful reference for the public health and emerging structures of EBOV -antibody complexes become available. In fact, as we were preparing this 2 5 8 manuscript, the crystal structure of mAb CA45 bound to GP1 and GP2 interface of EBOV GP 2 5 9
were published by Janus et al.
[25] Lastly, we believe our in-silico approach could be applied to future design and optimization efforts of antibodies. 
